Quantum BioPharma Targets Multiple Sclerosis and Alcohol-Related Brain Disorders with Novel Pipeline

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing a dual-pronged strategy to tackle neurological conditions that affect hundreds of millions worldwide. The company's pipeline includes Lucid-MS, a patented new chemical entity for multiple sclerosis (MS), and unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce the acute effects of intoxication and hangover.

Multiple sclerosis is one of the most common neurological diseases in young adults, with an estimated 2.9 million people living with MS globally, including about one million in the United States. The disease is typically diagnosed between ages 20 and 50, with a mean age of 32, and affects women at roughly twice the rate of men. Existing therapies often fall short, leaving patients with limited options. Lucid-MS takes a fundamentally different approach from current treatments, and its phase 2 development is supported by an ongoing imaging collaboration with Massachusetts General Hospital, as detailed in the company's press release.

In addition to MS, Quantum BioPharma is addressing the acute cognitive and physiological effects of alcohol intoxication with unbuzzd. This dietary supplement is formulated to aid alcohol metabolism and reduce hangover severity, targeting a common but often overlooked neurological stressor. The company's focus on two distinct areas of unmet need underscores its commitment to improving outcomes for patients with brain disorders.

Investors can access the latest news and updates on QNTM in the company's newsroom at https://ibn.fm/QNTM. For full terms of use and disclaimers, refer to the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.